Crossmark Global Holdings Inc. Acquires 5,229 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crossmark Global Holdings Inc. increased its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating) by 15.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,519 shares of the company’s stock after purchasing an additional 5,229 shares during the period. Crossmark Global Holdings Inc.’s holdings in Takeda Pharmaceutical were worth $513,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Ronald Blue Trust Inc. acquired a new stake in Takeda Pharmaceutical in the 2nd quarter valued at approximately $34,000. Allworth Financial LP raised its position in Takeda Pharmaceutical by 435.6% in the 3rd quarter. Allworth Financial LP now owns 2,871 shares of the company’s stock valued at $37,000 after buying an additional 2,335 shares during the last quarter. CWM LLC raised its position in Takeda Pharmaceutical by 102.4% in the 2nd quarter. CWM LLC now owns 3,615 shares of the company’s stock valued at $51,000 after buying an additional 1,829 shares during the last quarter. National Bank of Canada FI acquired a new stake in Takeda Pharmaceutical in the 3rd quarter valued at approximately $59,000. Finally, Hexagon Capital Partners LLC raised its position in Takeda Pharmaceutical by 311.2% in the 3rd quarter. Hexagon Capital Partners LLC now owns 4,716 shares of the company’s stock valued at $61,000 after buying an additional 3,569 shares during the last quarter. Institutional investors own 2.05% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.4 %

Shares of Takeda Pharmaceutical stock opened at $16.27 on Monday. The business’s 50 day simple moving average is $15.10 and its 200 day simple moving average is $14.14. Takeda Pharmaceutical Company Limited has a 52-week low of $12.28 and a 52-week high of $16.30. The firm has a market cap of $50.45 billion, a PE ratio of 30.13 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 1.15.

Takeda Pharmaceutical (NYSE:TAKGet Rating) last announced its earnings results on Thursday, October 27th. The company reported $0.52 earnings per share (EPS) for the quarter. The business had revenue of $7.26 billion for the quarter. Takeda Pharmaceutical had a return on equity of 12.76% and a net margin of 5.60%. On average, analysts predict that Takeda Pharmaceutical Company Limited will post 2.1 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

(Get Rating)

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience.

Featured Articles

Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Company Limited (NYSE:TAKGet Rating).

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.